other material
confidence high
sentiment positive
materiality 0.85
Pyxis Oncology MICVO Phase 1 shows 46% ORR monotherapy, 71% ORR with Keytruda in HNSCC
Pyxis Oncology, Inc.
- MICVO monotherapy at 5.4 mg/kg: 46% confirmed ORR (6/13), 92% DCR in 2L+ R/M HNSCC; no Grade 4/5 TRAEs.
- MICVO + Keytruda (3.6/4.4 mg/kg): 71% confirmed ORR (5/7), 100% DCR in 1L/2L+ HNSCC; no TRAE discontinuations.
- Sold Enzeshu royalty rights for $11M one-time cash; cash runway extends into Q4 2026.
- Monotherapy update expected mid-2026; combo update in 2H26; FDA alignment on pivotal study design obtained.